SINOVAC BIOTECH LTD

Drug Name	Phase	Indication	Designations	Patent
Vaccine manufactured at commercialized scale	Phase 3	Varicella	-	-
Sinovac PCV13	Phase 3	Pneumococcal Infectious Disease	-	-
investigational 23-valent PPV	Phase 3	Pneumococcal Infections	-	-
investigational live attenuated mumps vaccine	Phase 3	Mumps	-	-
400U /0.5ml EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
control live attenuated mumps vaccine	Phase 3	Mumps	-	-
Inactivated COVID-19 Vaccine	Phase 3	COVID-19	-	-
Investigational live attenuated varicella vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine,Inactivated	Phase 3	COVID-19	-	-
Varicella Vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)	Phase 3	COVID-19	-	-
sIPV-bOPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Investigational sIPV	Phase 3	Poliomyelitis	-	-
Sinovac rabies vaccine	Phase 3	Rabies (Healthy Volunteers)	-	-
PROVARIX	Phase 3	Varicella (Chickenpox)	-	-
Quadrivalent influenza vaccine(0.5ml)	Phase 3	Seasonal Influenza	-	-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Phase 3	Seasonal Influenza	-	-
Experimental vaccine	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine(0.25ml)	Phase 3	Seasonal Influenza	-	-
bivalent enterovirus vaccine (Vero cell), inactivated	Phase 3	Hand, Foot, and Mouth Disease（HFMD)	-	-
Sabin Strain Inactivated Poliovirus Vaccine	Phase 3	Poliomyelitis	-	-
three consecutive lots of EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine	Phase 3	Seasonal Influenza	-	-
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV	Phase 3	Influenza	-	-
Investigational tetanus vaccine, adsorbed	Phase 3	Tetanus	-	-
36-71 months old children-experimental EV71 vaccine.	Phase 3	Hand, Foot and Mouth Disease	-	-
sIPV-sIPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14	Phase 3	Covid19	-	-
Trivalent influenza vaccine (contains B/Victoria strain)	Phase 3	Seasonal Influenza	-	-
Sinovac Low-dosage PCV24	Phase 2	Pneumococcal Infectious Disease	-	-
Single-dose regimen of high dosage investigational sIPV	Phase 2	Poliomyelitis	-	-
pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Pandemic Influenza	-	-
100U EV71 vaccine with adjuvant	Phase 2	Infection, Viral, Enterovirus	-	-
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Influenza	-	-
Low-dose experimental vaccine	Phase 2	Herpes Zoster	-	-
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated	Phase 2	Hand, Foot and Mouth Disease	-	-
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)	Phase 2	Hand, Foot, and Mouth Disease (HFMD)	-	-
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain	Phase 2	COVID-19	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule	Phase 2	COVID-19	-	-
Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
Oral hexavalent reassortant rotavirus attenuated live vaccine	Phase 2	Rotavirus Gastroenteritis	-	-
Sinovac PCV24	Phase 2	Pneumococcal Infectious Disease	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
SARS-CoV-2 Inactivated Vaccine	Phase 2	COVID-19	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

SINOVAC BIOTECH LTD

Market Overview

SVA News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals